CLDX vs NTLA
Celldex Therapeutics, Inc. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CLDX | NTLA |
|---|---|---|
| Revenue | $1.5M | $67.7M |
| Net income | $-258.8M | $-412.7M |
| Gross margin | 87.1% | · |
| Net margin | · | −609.9% |
| Return on equity | −40.6% | −53.5% |
| Diluted EPS | −$3.90 | −$3.81 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-213.7M | $-395.9M |
| Equity | $527.2M | $671.4M |
| Net debt / equity | · | · |
| Current ratio | 10.49× | 5.08× |
| Revenue CAGR 5y | −26.9% | 3.1% |
| Profit CAGR 5y | · | · |
NTLA bills 43.8× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CLDX | NTLA |
|---|---|---|
| FY2025 | $1.5M | $67.7M |
| FY2024 | $7.0M | $57.9M |
| FY2023 | $6.9M | $36.3M |
| FY2022 | $2.4M | $52.1M |
| FY2021 | $4.7M | $33.1M |
| FY2020 | $7.4M | $58.0M |
| FY2019 | $3.6M | $43.1M |
| FY2018 | $9.5M | $30.4M |
| FY2017 | $12.7M | $26.1M |
| FY2016 | $6.8M | $16.5M |
Bottom line
| Fiscal year | CLDX | NTLA |
|---|---|---|
| FY2025 | $-258.8M | $-412.7M |
| FY2024 | $-157.9M | $-519.0M |
| FY2023 | $-141.4M | $-481.2M |
| FY2022 | $-112.3M | $-474.2M |
| FY2021 | $-70.5M | $-267.9M |
| FY2020 | $-59.8M | $-134.2M |
| FY2019 | $-50.9M | $-474.2M |
| FY2018 | $-151.2M | $-85.3M |
| FY2017 | $-93.0M | $-67.5M |
| FY2016 | $-128.5M | $-31.6M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$66,126,000 | NTLA |
| FY2024 | −$50,857,000 | NTLA |
| FY2023 | −$29,392,000 | NTLA |
| FY2022 | −$49,764,000 | NTLA |
| FY2021 | −$28,402,000 | NTLA |
| FY2020 | −$50,576,000 | NTLA |
| FY2019 | −$39,530,000 | NTLA |
| FY2018 | −$20,896,000 | NTLA |
| FY2017 | −$13,374,000 | NTLA |
| FY2016 | −$9,693,000 | NTLA |
NTLA has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's return on equity has been more volatile than CLDX's over the 9 comparable fiscal years — 43.0 percentage points of standard deviation against 16.9.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CLDX and NTLA over these 9 fiscal years — CLDX led in 6 and NTLA in 3.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.